AbbVie

AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois. It became an independent publicly traded company in 2013 after being separated from Abbott, taking with it Abbott’s established pharmaceutical research and commercial operations. AbbVie focuses on immunology, oncology, neuroscience, ophthalmology, gastroenterology, women’s health, and related therapeutic areas. Its portfolio has included Humira, Skyrizi, Rinvoq, Imbruvica, and other prescription medicines, as well as therapeutic and aesthetic products associated with the Allergan business. Humira was for many years a central product, while the company has sought to diversify its revenue base as biosimilar competition increased after the loss of key exclusivity protections. AbbVie has also expanded through research partnerships, licensing, and acquisitions, including the acquisition of Allergan. Its core business is the research, development, and commercialization of prescription medicines and related healthcare products; it is not a banking or general financial-services brand.

AbbVie was created as part of Abbott Laboratories’ separation of its research-based pharmaceutical operations. The company was formed in 2012 and began operating as an independent public company in January 2013. Its corporate name linked the Abbott heritage with “vie,” a word element associated with life. The new company inherited established medicines, research capabilities, employees, and commercial infrastructure, with Humira becoming its defining product. Humira’s success gave AbbVie a powerful position in immunology. The medicine was approved for a broad set of autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. At the same time, its importance made the company vulnerable to the eventual loss of exclusivity. AbbVie pursued patent and lifecycle-management strategies while developing replacement products and expanding into other therapeutic areas. During its first years, AbbVie supplemented internal research with external alliances and acquisitions. In 2014 it acquired ImmuVen and entered collaborations with Infinity Pharmaceuticals and Calico. The company abandoned its proposed acquisition of Shire in 2014 after changes to United States tax rules undermined the transaction’s intended structure; AbbVie paid a reported $1.6 billion termination fee. In 2015 it acquired Pharmacyclics, obtaining Imbruvica and increasing its presence in hematologic oncology. In 2016 it acquired Stemcentrx and expanded collaborations in cystic fibrosis, inflammatory bowel disease, oncology, synthetic biology, and targeted immunotherapy. The largest transformation came through the Allergan transaction. Announced in 2019 and completed in 2020, the approximately $63 billion acquisition added Botox and Allergan’s aesthetics business, as well as products and development assets in neuroscience, eye care, gastroenterology, and other fields. Regulatory review required divestitures including brazikumab and the pancreatic enzyme products Zenpep and Viokace. The acquisition diversified AbbVie beyond immunology and created a much broader commercial platform. The COVID-19 pandemic produced a short-lived investigation of Kaletra, the lopinavir/ritonavir combination used for HIV. AbbVie worked with health authorities to evaluate whether the medicine could have value against COVID-19, but an early randomized study did not demonstrate usefulness in severe disease. In the same period, Israel announced it could override patent protections for access to the medicine; AbbVie subsequently stated that it would not enforce its Kaletra patents. After 2020, AbbVie continued to build positions in immunology, oncology, and neuroscience. Allergan Aesthetics acquired Soliton in 2021, while AbbVie acquired TeneoOne and its multiple-myeloma program. In 2022 it bought Syndesi Therapeutics and DJS Antibodies, adding neuroscience and antibody research capabilities. Humira biosimilar competition began to intensify in 2023, increasing the importance of Skyrizi and Rinvoq as successor growth products. In 2024 AbbVie completed acquisitions of ImmunoGen, Landos Biopharma, and Cerevel Therapeutics. ImmunoGen brought Elahere, an antibody-drug conjugate for ovarian cancer. Landos added NX-13, an investigational gastrointestinal immunology asset. Cerevel expanded the neuroscience pipeline with programs aimed at disorders including schizophrenia, Parkinson’s disease, and other neurological conditions. AbbVie also acquired Aliada Therapeutics in 2024 to add another neuroscience platform. The company’s growth strategy combines commercial execution with business development. AbbVie promotes prescription products through healthcare professionals, patient-support programs, digital channels, television, and disease-awareness initiatives. Its public-facing communications increasingly focus on patient experiences and the effect of chronic disease on everyday life. The “I Am” corporate campaign, for example, portrayed people with psoriasis, Parkinson’s disease, blood cancer, and other conditions through identities broader than their diagnoses, while also featuring scientists involved in developing medicines. AbbVie has also faced sustained criticism. Allegations have concerned patent thickets and other methods that may delay biosimilar competition, drug-pricing practices, marketing arrangements, tax planning, and opioid promotion by an Allergan subsidiary. The company settled some disputes financially while denying wrongdoing in certain cases. A United Kingdom court dismissed AbbVie’s 2018 procurement challenge against NHS England concerning hepatitis C treatments. These issues have made AbbVie a recurring subject in debates about pharmaceutical competition, affordability, and intellectual-property policy. In June 2024, Robert A. Michael became chief executive officer and Richard Gonzalez became executive chairman. AbbVie continues to focus on replacing Humira-related revenue with growth in immunology, aesthetics, oncology, and neuroscience, while using acquisitions and licensing agreements to replenish its research pipeline.

1. 2024ImmunoGen acquisition closes

   AbbVie completed its acquisition of ImmunoGen and added Elahere to its oncology portfolio.

   Source
2. 2024Leadership transition

   Robert Michael became CEO and Richard Gonzalez became executive chairman.

   Source
3. 2023Humira biosimilar competition begins

   Biosimilar versions of Humira began entering the United States market, intensifying pressure on AbbVie’s former leading product.

   Source
4. 2020Allergan transaction closes

   The Allergan acquisition closed, adding Botox, aesthetics, neuroscience, and other businesses.

   Source
5. 2016Stemcentrx acquisition

   AbbVie announced an acquisition of Stemcentrx valued at up to $9.8 billion, expanding its oncology pipeline.

   Source
6. 2015Pharmacyclics acquisition

   AbbVie acquired Pharmacyclics, bringing Imbruvica into its oncology portfolio.

   Source
7. 2013Public-company launch

   AbbVie began trading independently in January 2013.

   Source
8. 2012AbbVie is formed

   AbbVie was established as the planned spin-off of Abbott Laboratories’ research-based pharmaceutical business.

   Source

A diversified research-driven biopharmaceutical company with particular strength in immunology, specialty medicines, aesthetics, oncology, and neuroscience. AbbVie positions itself around innovative therapies for serious and chronic diseases, supported by global commercialization and acquisitions that replenish its pipeline.

• HumiraImmunology biologic

  Humira is the brand name for adalimumab, a tumor-necrosis-factor inhibitor administered by injection. It has been used across a wide range of autoimmune and inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. Humira was AbbVie’s foundational commercial product, but its importance also exposed the company to substantial revenue pressure when biosimilar competition began.

• SkyriziImmunology biologic

  Skyrizi is risankizumab, an interleukin-23 inhibitor used for several immune-mediated diseases. Its indications include plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. AbbVie has developed Skyrizi as one of its principal post-Humira growth products, supported by clinical expansion and substantial patient and professional communications.

• RinvoqImmunology small molecule

  Rinvoq is upadacitinib, an oral Janus kinase inhibitor used in inflammatory and autoimmune conditions, including certain forms of arthritis, atopic dermatitis, Crohn’s disease, and ulcerative colitis. Its oral format and expanding indications make it a central component of AbbVie’s immunology strategy and a major successor to Humira.

• BotoxMedical aesthetics and therapeutic medicine

  Botox is a botulinum toxin product used for both aesthetic procedures and therapeutic indications. AbbVie obtained the brand through the Allergan acquisition. The business operates across cosmetic treatment and medical applications, including certain neurological and muscular conditions, and is one of AbbVie’s most recognizable consumer-facing offerings.

• ImbruvicaOncology medicine

  Imbruvica is ibrutinib, a targeted oncology medicine used in several blood cancers and related hematological malignancies. AbbVie obtained rights and commercial participation through its 2015 acquisition of Pharmacyclics. The product helped establish AbbVie as a significant oncology company, although it has faced competition and pricing scrutiny.

• VenclextaOncology medicine

  Venclexta is venetoclax, a medicine used in the treatment of certain leukemias and lymphomas. It is part of AbbVie’s blood-cancer portfolio and was developed through collaboration with Genentech and Roche. Its mechanism and clinical use place it within the company’s targeted-therapy strategy in hematologic oncology.

• VraylarNeuroscience medicine

  Vraylar is cariprazine, a medicine used for schizophrenia and bipolar disorder. The product is part of AbbVie’s neuroscience portfolio and illustrates the company’s effort to build commercial depth beyond immunology and oncology.

• MavyretAntiviral medicine

  Mavyret is glecaprevir/pibrentasvir, a fixed-dose antiviral combination used to treat hepatitis C virus infection. It represents AbbVie’s contribution to direct-acting antiviral therapy and its broader focus on medicines addressing significant infectious diseases.

• EpkinlyBispecific oncology antibody

  Epkinly is epcoritamab, a bispecific antibody developed with Genmab for certain B-cell blood cancers. It is designed to engage immune cells against malignant B cells and adds a newer immuno-oncology modality to AbbVie’s hematology portfolio.

• ElahereAntibody-drug conjugate2022

  Elahere is an antibody-drug conjugate obtained through AbbVie’s acquisition of ImmunoGen. It is used in certain ovarian cancers and gives AbbVie a commercial foothold in a specialized oncology technology area. The acquisition was intended to accelerate AbbVie’s development and commercialization of the product.

• 2024Rinvoq and Skyrizi national television campaigns

  United States

  AbbVie maintained prominent television advertising for Rinvoq and Skyrizi across arthritis, eczema, psoriasis, Crohn’s disease, and ulcerative colitis.

  Outcome. The campaigns supported the company’s effort to shift attention toward its post-Humira immunology growth products.

  Source
• 2022Rinvoq extreme-sports television advertising

  United States

  A series of high-energy Rinvoq advertisements used scenarios such as helicopters, motorcycles, and rafting to dramatize the desire to return to activities affected by inflammatory disease.

  Outcome. The campaign extended Rinvoq’s direct-to-consumer presence across indications including eczema, arthritis, and ulcerative colitis.

  Source
• I Am

  United States

  A corporate campaign presenting people living with conditions treated by AbbVie as multidimensional individuals rather than as diagnoses. The campaign also highlighted employees and scientists involved in creating medicines and used digital, social, and out-of-home media.

  Outcome. The campaign sought to build an emotional connection with patients and communicate AbbVie’s patient-centered corporate identity.

  Source

• 2024Acquire ImmunoGenM&A

  AbbVie sought to accelerate its entry into antibody-drug conjugates and ovarian-cancer treatment.

  What changed. AbbVie completed the acquisition of ImmunoGen for $31.26 per share.

  Aftermath. ImmunoGen became part of AbbVie and contributed Elahere and related oncology capabilities.

  Transaction value. $10.1 billion (Completed February 12, 2024)

  Source
• 2024Acquire Landos BiopharmaM&A

  AbbVie wanted to strengthen its inflammatory bowel disease pipeline with a novel investigational asset.

  What changed. AbbVie completed the acquisition of Landos, adding NX-13 for study in ulcerative colitis and Crohn’s disease.

  Aftermath. Landos became part of AbbVie and its shares ceased trading on Nasdaq.

  Per-share consideration. $20.42 per share plus a contingent value right of up to $11.14 per share (Completed May 23, 2024)

  Source
• 2020Stop enforcing Kaletra patents during the pandemicStrategy

  Lopinavir/ritonavir was being evaluated as a possible COVID-19 treatment, while governments and health groups raised concerns about access.

  What changed. AbbVie announced that it would stop enforcing patents covering Kaletra.

  Aftermath. Clinical evidence did not support Kaletra as an effective treatment for severe COVID-19, but the decision removed a patent-enforcement barrier during the emergency.

  Source
• 2019Acquire AllerganM&A

  AbbVie sought to diversify beyond Humira and expand in aesthetics, neuroscience, eye care, and established medicines.

  What changed. AbbVie agreed to acquire Allergan in a transaction valued at approximately $63 billion.

  Aftermath. The transaction closed in 2020 after regulatory review and required selected asset divestitures.

  Transaction value. $63 billion (Announced 2019; completed 2020)

  Source
• 2014Withdraw from the Shire acquisitionM&A

  AbbVie had pursued Shire in a transaction that would have created a much larger pharmaceutical group and used a tax-inversion structure.

  What changed. The company abandoned the transaction after changes to U.S. Treasury rules reduced the expected tax advantages.

  Aftermath. AbbVie paid a reported $1.6 billion termination fee and continued pursuing growth through other acquisitions and internal development.

  Termination fee. $1.6 billion (2014)

  Source

• 2024Trade-secret lawsuit against BeiGeneControversy

  AbbVie sued BeiGene, alleging that a former AbbVie scientist took confidential information that was used in developing a competing blood-cancer treatment. The allegations were disputed and remained litigation claims rather than established findings.

  Source
• 2022Opioid-marketing settlement involving AllerganControversy

  AbbVie agreed to pay up to $2.37 billion to resolve U.S. litigation involving alleged opioid marketing by its Allergan unit. AbbVie denied wrongdoing.

  Source
• 2021Senate investigation into tax practicesControversy

  The United States Senate Finance Committee examined whether AbbVie used provisions of the 2017 tax law and offshore intellectual-property structures to reduce its U.S. tax liability.

  Source
• 2020Humira nurse-ambassador allegationsControversy

  AbbVie agreed to pay $24 million to resolve allegations concerning kickbacks connected with promotion of Humira through nurse-ambassador programs.

  Source
• 2018TriCor marketing settlementControversy

  AbbVie agreed to pay $25 million to resolve allegations that unlawful kickback arrangements were used to promote TriCor. The resolution did not establish a criminal conviction by itself, and the company’s legal position should be distinguished from the allegations.

  Source

• 2026AbbVie reports 2025 full-year results

  AbbVie reported full-year 2025 results showing continued growth in neuroscience and key products including Vraylar, Botox Therapeutic, Ubrelvy and Qulipta. The company also reiterated its 2026 strategic priorities.

  OtherProduct generation
  Source
• 2026AbbVie announces agreement with the U.S. administration on access and investment

  AbbVie announced a voluntary agreement involving lower Medicaid prices, expanded direct-to-patient access and a commitment of $100 billion in U.S. research and capital investment over ten years. The company said the agreement also included tariff and future pricing-mandate exemptions.

  PricingRegulation
  Source
• 2026AbbVie announces proposed acquisition of Apogee Therapeutics

  AbbVie announced a proposed acquisition of Apogee Therapeutics to deepen its immunology portfolio. The transaction was reported as anticipated to close in the third quarter of 2026, subject to customary conditions.

  M&A
  Source
• 2025AbbVie acquires Nimble Therapeutics and partners with Neomorph

  AbbVie completed the acquisition of Nimble Therapeutics and announced a collaboration with Neomorph to develop molecular-glue degraders for oncology and immunology. These transactions reflected the company’s emphasis on external innovation and new drug modalities.

  M&A
  Source
• 2024AbbVie completes ImmunoGen acquisition

  AbbVie completed its acquisition of ImmunoGen, adding the antibody-drug conjugate Elahere and an oncology development platform.

  M&AProduct launch
  Source
• 2024Robert Michael succeeds Richard Gonzalez as CEO

  Robert Michael became chief executive officer, while Richard Gonzalez moved to the role of executive chairman.

  Leadership change
  Source
• 2024AbbVie completes acquisition of Landos Biopharma

  The acquisition added NX-13, an investigational immunology asset being studied for ulcerative colitis and Crohn’s disease.

  M&A
  Source
• 2024AbbVie completes acquisition of ImmunoGen

  AbbVie completed its acquisition of ImmunoGen, adding Elahere and strengthening its ovarian-cancer and antibody-drug-conjugate capabilities.

  M&AProduct launch
  Source
• 2024Robert Michael becomes chief executive officer

  Robert A. Michael succeeded Richard Gonzalez as chief executive officer in 2024. Gonzalez moved to the role of executive chairman.

  Leadership change
  Source
• 2024AbbVie completes acquisition of Cerevel Therapeutics

  AbbVie acquired Cerevel Therapeutics for approximately $8.7 billion, expanding its neuroscience pipeline and adding investigational and commercial assets in psychiatric and neurological diseases.

  M&A
  Source
• 2024AbbVie completes acquisition of Aliada Therapeutics

  The acquisition of Aliada Therapeutics expanded AbbVie’s neuroscience research portfolio, including approaches intended to improve delivery of therapeutic agents into the brain.

  M&A
  Source
• 2023Humira biosimilar competition begins in the United States

  Humira began facing U.S. biosimilar competition in January 2023, marking a major commercial transition for AbbVie and increasing the strategic importance of Skyrizi, Rinvoq and newer pipeline products.

  Product generationPricingOther
  Source
• 2022AbbVie acquires Syndesi Therapeutics

  AbbVie acquired Syndesi Therapeutics for up to approximately $1 billion, obtaining synaptic-vesicle-protein-2A modulators and the lead neuroscience program SDI-118.

  M&A
  Source
• 2020AbbVie ends enforcement of Kaletra patents during the COVID-19 response

  After evaluating lopinavir/ritonavir as a possible COVID-19 treatment and facing pressure concerning access, AbbVie said it would stop enforcing patents covering Kaletra.

  RegulationOther
  Source
• 2020AbbVie completes acquisition of Allergan

  The acquisition closed on May 8, 2020, creating a larger and more diversified biopharmaceutical company. AbbVie subsequently operated Allergan Aesthetics as a dedicated business.

  M&A
  Source
• 2020AbbVie evaluates Kaletra during the COVID-19 pandemic

  AbbVie worked with health authorities and researchers to evaluate lopinavir/ritonavir, marketed as Kaletra or Aluvia, as a possible COVID-19 treatment. Randomized evidence later did not support its use for severe COVID-19, and AbbVie said it would not enforce relevant patents during the emergency.

  OtherRegulation
  Source
• 2020Allergan Aesthetics launches a new global brand identity

  Allergan Aesthetics introduced a global identity emphasizing confidence, diversity and inclusion while presenting its aesthetics portfolio under the AbbVie umbrella.

  CampaignOther
  Source
• 2019AbbVie announces Allergan acquisition

  AbbVie agreed to acquire Allergan in a transaction valued at approximately $63 billion, expanding its presence in aesthetics, neuroscience, and established medicines.

  M&A
  Source
• 2019AbbVie announces acquisition of Allergan

  AbbVie announced an agreement to acquire Allergan in a transaction valued at approximately $63 billion. The proposed combination was designed to diversify AbbVie into aesthetics, neuroscience, eye care and other specialty areas.

  M&A
  Source
• 2015AbbVie acquires Pharmacyclics

  The transaction added Imbruvica and strengthened AbbVie’s oncology portfolio, particularly in blood cancers.

  M&A
  Source
• 2014AbbVie ends proposed acquisition of Shire

  AbbVie abandoned its proposed acquisition of Shire after changes to U.S. tax rules weakened the rationale for the transaction. The company paid a reported $1.6 billion termination fee.

  M&AOther
  Source
• 2013AbbVie becomes an independent public company after separation from Abbott Laboratories

  AbbVie began trading as a separate public company following the spin-off of Abbott Laboratories’ research-based pharmaceutical business.

  M&AOther
  Source
• 2013AbbVie launches as an independent biopharmaceutical company

  AbbVie began trading as an independent public company after separating from Abbott Laboratories. The launch established the company as a focused biopharmaceutical business with a global commercial and research base.

  OtherProduct launch
  Source

1. AbbVie
2. AbbVie Completes Acquisition of ImmunoGen
3. AbbVie Completes Acquisition of Landos Biopharma
4. Explore the Human Side of AbbVie’s I Am Campaign
5. AbbVie Continues with Extreme Sporting Rinvoq TV Ad Theme
6. AbbVie Corporate Campaign Celebrates Patients and Scientists
7. Leadership transition
8. I Am
9. Rinvoq and Skyrizi national television campaigns
10. TriCor kickback and off-label marketing settlement
11. AbbVie reports 2025 full-year results
12. AbbVie announces agreement with the U.S. administration on access and investment
13. AbbVie announces proposed acquisition of Apogee Therapeutics
14. AbbVie acquires Nimble Therapeutics and partners with Neomorph
15. Robert Michael becomes chief executive officer
16. AbbVie completes acquisition of Allergan
17. Allergan Aesthetics launches a new global brand identity
18. AbbVie launches as an independent biopharmaceutical company